MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc., a company developing protein and antibody therapeutics, announced today the presentation of results from pre-clinical studies evaluating two humanized monoclonal antibody therapeutics, including the company’s lead candidate, XmAb™2513, during the American Society of Hematology (ASH) 49th Annual Meeting and Exposition, December 8-11, 2007 in Atlanta, GA. Xencor’s XmAb candidates contain proprietary engineered Fc domains that greatly increase anti-tumor potency.
